About the Authors

Aaron S. Kesselheim
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America

Aaron S. Kesselheim
Harvard Medical School, Boston, Massachusetts, United States of America

Michelle M. Mello
Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, United States of America

David M. Studdert
School of Law, University of Melbourne, Melbourne, Australia

David M. Studdert
School of Population Health, University of Melbourne, Melbourne, Australia

Corresponding Author

akesselheim@partners.org

Competing Interests

ASK reports consulting for the Alosa Foundation, a nonprofit organization that runs the Independent Drug Information Service and is not affiliated in any way with any pharmaceutical company. From 2008–2009, ASK served as an expert witness for the state of Texas in a lawsuit against Merck related to improper promotion of rofecoxib (Vioxx). From 2007–2008, ASK helped develop an educational program to encourage evidence-based prescribing, with funding from a grant derived from the settlement of a fraud case regarding improper promotion of gabapentin (Neurontin).

Author Contributions

ICMJE criteria for authorship read and met: ASK MMM DMS. Agree with the manuscript's results and conclusions: ASK MMM DMS. Designed the experiments/the study: ASK DMS. Analyzed the data: ASK DMS. Collected data/did experiments for the study: ASK DMS. Wrote the first draft of the paper: ASK. Contributed to the writing of the paper: ASK MMM DMS. Contributed to the design of the study: MMM.